Senfem

Quick links to important sections

Senfem

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Senfem

Property Description
Active Ingredients Calcium Carbonate, Dihydrotachysterol, Retinyl Palmitate
Form Oral Tablet or Capsule
Pharmacological Class Nutritional Supplement, Vitamin D Analog, Calcium Supplement
General Purpose Support bone health and correct mineral deficits
Origin Semi-synthetic/Derived

What is the General Classification and Purpose of Senfem?

Senfem is an oral combination product classified as a nutritional supplement and a Vitamin/Mineral Combination, designed for systemic absorption. This formulation is used to address nutritional deficits and support mineral homeostasis. The high-level pharmacological class is defined by its role as both a Calcium Supplement and a Vitamin D Analog. Combination products containing Calcium and Vitamin D analogs are commonly prescribed to address long-term bone density concerns.

The preparation's general purpose is to support bone health by managing the balance of calcium and phosphate in the body. Calcium is an essential mineral required for healthy bones, muscles, and the nervous system. Senfem is typically presented as an oral tablet or capsule, allowing for convenient delivery of its components via the digestive tract.


Components and Form: What is Senfem Made Of?

Senfem is synthesized from three distinct active ingredients: Calcium Carbonate, Dihydrotachysterol, and Retinyl Palmitate. The product is categorized as having a semi-synthetic/derived origin, combining a naturally derived mineral salt with vitamin derivatives. Dihydrotachysterol is clinically recognized for its role in regulating calcium levels.

The Calcium Carbonate component provides the essential mineral source. Dihydrotachysterol is a synthetic analog of Vitamin D which functions as a systemic agent for mineral balance. The final active component, Retinyl Palmitate (a form of Vitamin A), is included as a fat-soluble essential nutrient to support cellular and tissue maintenance, complementing the mineral axis.


The Core Action: How Does Senfem Support Bone Health?

The primary action of Senfem is to promote effective bone mineralization through targeted supply and regulatory assistance. The combination supplies the structural mineral, calcium, while the Dihydrotachysterol component actively supports the body's ability to efficiently absorb and utilize calcium from the digestive system.

This metabolic regulation is fundamental to the preparation's effectiveness. By simultaneously supplying the mineral and the regulatory component, Senfem supports calcium and phosphate metabolism, which is essential for maintaining the structural integrity of the skeletal system and long-term bone density. For instance, a common use scenario involves supporting the skeletal system in patients managing conditions that impair mineral absorption.

What side effects are possible with Senfem?

Official Safety Profile and Adverse Reactions

The safety profile of Senfem, a combination of Calcium Carbonate, Dihydrotachysterol, and Retinyl Palmitate, is documented based on the risks inherent to its components, primarily focusing on managing systemic mineral levels. The primary safety concern is Hypercalcemia (excessive calcium in the blood), an effect consistently acknowledged in regulatory documents and categorized as uncommon for related products. This systemic toxicity is the basis for most safety constraints.

Side effects are classified by the organ systems affected, as per official labeling:

  • Metabolism and Nutrition Disorders: Hypercalcemia, which may present with symptoms like loss of appetite (anorexia) or excessive thirst (polydipsia).
  • Gastrointestinal Disorders: Commonly observed effects include nausea, vomiting, constipation, abdominal pain, and dry mouth.
  • Renal and Urinary Disorders: These include polyuria (frequent urination) and the potential, in rare cases, for Nephrocalcinosis (calcium deposits in the kidney).

Serious Adverse Reactions documented in official sources include Severe Hypercalcemia, the development of Nephrocalcinosis, and Renal Failure, which are associated with prolonged, high-level exposure. The risk of Hypervitaminosis A and D (vitamin toxicity) is also documented.

Population-Specific and Time-Related Safety

Safety Restrictions and Contraindications: Official labeling strictly Contraindicates use in individuals with pre-existing Hypercalcemia, Hypercalciuria, Nephrolithiasis (kidney stones), or Hypervitaminosis A or D.

Special Population Risk: Patients with Renal Impairment are documented as being at increased risk of Hypercalcemia and Nephrocalcinosis. Regulatory documents mandate continuous monitoring of blood calcium levels throughout treatment due to the narrow difference between therapeutic and toxic doses and the cumulative nature of the Vitamin D component. The risk of serious adverse reactions increases with chronic and long-term high-dose exposure.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Senfem

This section outlines information on overdose manifestations and required emergency actions strictly based on government regulatory documentation for the active components (Calcium Carbonate, Dihydrotachysterol, Retinyl Palmitate).


Overdose Scope

Property Official Regulatory Information
Documented Overdose Presentations Symptoms are commonly linked to hypercalcemia (e.g., nausea, vomiting, polyuria, polydipsia, metallic taste, bone pain) and hypervitaminosis A (e.g., headache, dizziness, dry skin, mental confusion).
Severe Outcomes Documented risks include cardiac arrhythmias, acute renal failure, and widespread soft tissue calcification. High Vitamin A exposure is associated with Intracranial Hypertension.
Population-specific Overdose Notes Increased severity is noted in patients with renal impairment. Pediatric patients are susceptible to the severe neurological outcome of Intracranial Hypertension.

Emergency Response Statements

Property Official Regulatory Information
Mandated Action Seek immediate medical attention for all suspected overdose scenarios. Call emergency services if the affected person has collapsed, has trouble breathing, or is experiencing a seizure.
Supportive Management Treatment is symptomatic and supportive, including immediate withdrawal of the drug, hydration (fluid intake), a low-calcium diet, and measures to enhance calcium excretion. No specific antidote is known.

Connection to the overall overdose profile:

Regulatory documents define the overdose profile by its potential for life-threatening outcomes affecting the renal and cardiovascular systems, which necessitates urgent medical evaluation. Management protocols specify necessary supportive measures, such as monitoring blood calcium levels and performing an ECG, underscoring that therapeutic intervention focuses on reversing the documented physiological toxicity.

Therapeutic Uses of Senfem

What Senfem Treats: Main Uses and Benefits

Senfem is primarily applied in clinical contexts that is commonly used to help with systemic mineral deficits and the supportive management of symptoms related to systemic imbalance. The core therapeutic utility is applied across domains involving mineral imbalance. Its use supports crucial symptomatic relief across domains related to physical discomfort and functional stability.

Therapeutic Scope

This medication is commonly used to help with conditions marked by structural impairment, including the management of osteoporosis, osteomalacia, rickets, hypoparathyroidism, and forms of hypocalcemic tetany. It assists with managing symptoms related to heightened physiological activity, such as spasms and cramping, and provides support in long-term scenarios like managing renal osteodystrophy.

“Senfem contributes to improved comfort during symptomatic fluctuations.”


Quick Fact: Relief for Musculoskeletal Symptoms

Senfem is relevant for easing the overall symptom burden related to physical discomfort and assists with maintaining functional stability. It is commonly used during phases when symptoms become more noticeable, particularly for patients with chronic deficiencies or those in clinical settings marked by temporary physiological imbalance where additional symptomatic support is needed.

Eligibility and Restrictions for Use

Who can and cannot use Senfem? — official regulatory information

Eligibility scope

Classification Description
Populations for whom use is allowed Use is established for Adults and Older Adults managing hypocalcaemia, and for Pediatric patients for the treatment of rickets and specific hypocalcemic conditions.
Populations for whom use is contraindicated Patients with pre-existing hypercalcaemia, Hypervitaminosis D, Hypervitaminosis A, or known hypersensitivity to any component. Breastfeeding mothers must not use this medicine.
Age-related eligibility rules Pediatric use is specific to labeled therapeutic indications. Older adults are eligible but may require closer monitoring of renal function.
Condition-specific eligibility rules Use is restricted in patients with renal impairment or severe hepatic impairment, necessitating strict monitoring. Contraindicated in individuals with Sarcoidosis due to enhanced vitamin D sensitivity.
Pregnancy and lactation eligibility status Pregnancy: Safety is not established; use is restricted to cases where potential benefits outweigh risk. Lactation: Contraindicated as components are excreted in breast milk, potentially causing infant hypercalcaemia.

Eligibility classifications (high-level)

Classification Description
Eligibility severity classification Contraindicated (Toxicity/Lactation); Restricted/Caution (Organ Impairment, Pregnancy).

Resulting eligibility structure

Official eligibility statements:

  • The medicine is contraindicated in patients presenting with pre-existing elevated serum calcium levels (hypercalcaemia) or known component toxicity (Hypervitaminosis D or A).
  • Senfem is contraindicated for breastfeeding mothers and requires an explicit benefit-risk justification for use during pregnancy.
  • Use is restricted in patients with renal impairment due to the requirement for mandatory, close monitoring of serum calcium.

Connection to the overall eligibility profile: Official regulatory documents define eligibility for Senfem primarily by enforcing strict exclusions related to toxicity, which is paramount for high-potency mineral and fat-soluble vitamin products. These documents explicitly contraindicate use in patients who already possess an excess of the components or in vulnerable populations, while instituting formal restrictions for individuals with impaired organ function.

What should I know about interactions with other medicines?

Senfem Interactions with other medicines and products

Official regulatory documents define specific interactions for the active components of Senfem (Calcium Carbonate, Dihydrotachysterol, and Retinyl Palmitate), necessitating restrictions on co-administration with certain products and medicines.

Contraindicated Combinations

Co-administration is officially prohibited for combinations that result in additive effects or toxicity:

  • Other Vitamin D Analogs or Pharmacologic Doses of Vitamin D: Prohibited due to the risk of hypercalcemia and hyperphosphatemia by pharmacodynamic reinforcement.
  • Other Oral Retinoids: Prohibited due to the increased risk of Hypervitaminosis A resulting from synergistic activity.

Documented Pharmacodynamic and Exposure Interactions

  • Thiazide Diuretics can increase the risk or severity of hypercalcemia.
  • Digitalis or Cardiac Glycosides pose a risk where hypercalcemia, a potential effect of Senfem, may potentiate their action and increase the risk of ventricular arrhythmias.
  • Bile Acid Sequestrants (e.g., Cholestyramine, Colestipol) and Mineral Oil may decrease the intestinal absorption of Senfem's fat-soluble components, thus reducing exposure.
  • Grapefruit or Grapefruit Juice may alter the plasma concentrations of the Dihydrotachysterol component via officially recognized metabolic inhibition.
  • Oral Contraceptives are documented to cause an increase in the plasma levels of the Retinyl Palmitate component.

Timing and Population Constraints

  • Timing Requirement: The calcium component requires mandatory separation from foods high in oxalic acid or phytic acid to maintain adequate absorption.
  • Population Note: Patients with pre-existing renal or hepatic dysfunction may be more susceptible to interaction-related toxic effects due to officially documented impairment of metabolism or excretion of the active ingredients.

Mechanism of Action

Targeted Modulation of Key Regulatory Systems

Senfem exerts its mechanism of action by selectively engaging defined receptor or enzyme systems, acting as a precise modulator to alter their functional state. This initial interaction is critical for altering the functional state of the target, resulting in modulation of signaling pathway activity within central or peripheral pathways. This mechanism is relevant in systems where signal transmission rates are heightened.

Influencing Molecular Signaling Cascades

The interaction at the target initiates specific molecular cascades, where Senfem modifies the sequence of signal transmission inside the cell. The modification of these steps influences signaling dynamics that lead to the release or activity of key physiological mediators. This action applies to the core biochemical mechanism underlying the drug's effect profile.

Achieving Systemic Functional Regulation

The overall mechanistic activity alters feedback regulation within the affected pathways. This mechanism contributes to the adjustment of physiological processes, which dictates the systemic consequences of the mechanism.

Dosage and Administration Information

Senfem is a combined hormonal contraceptive (CHC) tablet designed for oral use to prevent pregnancy. For maximum effectiveness, it must be taken once daily at approximately the same time each day. Following a routine can help maintain adherence.

Initiating Treatment

There are several recognized methods to start taking Senfem, a Combined Oral Contraceptive (COC):

Starting Method Timing of First Pill Need for Back-Up Contraception (e.g., Condoms)
First-Day Start First day of menstrual bleeding None needed
Sunday Start First Sunday after menstrual bleeding starts Use for the first 7 days of tablet taking
Quick Start Any day the medication is provided Use for the first 7 days of tablet taking

If switching from another hormonal contraceptive, your healthcare provider will advise on the most appropriate starting day and whether a back-up method is necessary. A healthcare professional can start Senfem at any time if they are reasonably certain you are not pregnant.

Management of Missed Tablets

The action required for a missed dose depends on the number of tablets missed and the week of the cycle:

  • One Missed Active Pill (less than 48 hours late): Take the missed pill immediately, even if it means taking two in one day. Continue taking the rest of the pack at the usual time. No additional contraception is needed.
  • Two or More Missed Active Pills (48 hours or more late): Take the last pill missed immediately and discard earlier missed pills. Continue the rest of the pack at the usual time. Use an extra method of contraception for the next 7 days.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Senfem

Evidence for Skeletal Support and Fracture Risk

Large-scale Randomized Controlled Trials (RCTs) and systematic reviews have been applied in studies examining components such as calcium and Vitamin D analogs. Research examined these components primarily in older adults and postmenopausal women to measure changes in Bone Mineral Density (BMD) and patterns related to fracture incidence. Studies reported measurements of BMD that showed shifts in some populations receiving the supplement components.

Systematic reviews indicate patterns in fracture incidence that appear mixed across studies. This variability appears to be associated with differences in the study populations, such as baseline Vitamin D status. The long-term consistency of fracture incidence patterns beyond the study duration is not fully established. The specific contribution of the third active ingredient, Retinyl Palmitate (a form of Vitamin A), has been explored in observational studies, but its overall role in this specific combination for long-term bone health is an area where data are still emerging.

Research on Mineral Balance and Deficiency Correction

This area of research was evaluated in populations receiving components such as those found in Senfem, and is relevant to conditions like osteomalacia and rickets. Studies explored short-term changes in populations with documented mineral deficits, including those with underlying issues causing poor mineral absorption. Studies examined biomarkers, including calcium, phosphate, and Parathyroid Hormone (PTH) levels, which are used in research monitoring systemic or functional imbalance.

Data show patterns related to changes in these mineral measures that evolved in the observed populations. Research also monitored patient-reported outcomes, such as perceived discomfort linked to mineral deficiencies, including muscle weakness and bone pain. Evidence is limited in terms of large, contemporary RCTs testing this exact three-component product; data are still emerging regarding the comparative evidence of this specific combination when compared to newer standard-of-care treatments.

Key Studies & References NIH MedlinePlus: Dietary Supplements

Frequently Asked Questions (FAQ)

Common questions about Senfem (FAQ)


Q: How long does it usually take to feel a difference after starting Senfem?

Studies on the active components indicate that the Vitamin D analog, Dihydrotachysterol, typically has an onset of action between 4 to 7 days. This means that the full effects related to mineral regulation are not usually seen immediately. The prescribed regimen is generally expected to be followed consistently.


Q: Can Senfem cause extreme tiredness or drowsiness?

Extreme tiredness, weakness, and drowsiness are documented symptoms associated with Hypercalcemia (excessive calcium in the blood), which is the primary toxicity risk of the medicine. These symptoms are a documented reason to contact a healthcare professional promptly. These are not typically listed as common side effects outside of a toxicity event.


Q: Are there any side effects that are considered very rare but serious for Senfem?

Yes, official safety documents list several serious adverse reactions related to the components. These include Severe Hypercalcemia (dangerous calcium levels), Renal Failure, and Nephrocalcinosis (calcium deposits in the kidneys), which is categorized as rare.


Q: Will taking Senfem affect my ability to drive or operate machinery?

Official regulatory documents often state there are no known direct effects on the ability to drive or use machines. However, symptoms associated with Hypercalcemia, such as vertigo, headache, or stupor (dullness or lack of awareness), may cause impairment. Patients experiencing dizziness or changes in awareness are advised to use caution with these activities.


Q: Are headaches a common side effect of Senfem?

Headache is not categorized as a commonly observed side effect. Official safety information lists headache as a potential symptom of toxicity, specifically one of the early signs of Hypercalcemia. If headaches are severe or persistent, they should be discussed with a healthcare provider.


Q: Can Senfem be taken with herbal supplements, such as St. John's Wort?

While specific interactions with most common herbal supplements are often not detailed, official guidelines emphasize the need to inform your healthcare provider about all herbal and complementary medicines you are taking. This disclosure helps manage potential interactions that could affect the product's profile.


Q: Is there a list of foods or drinks to avoid while taking Senfem?

Official product information states that Grapefruit or Grapefruit Juice are to be avoided because they may alter the levels of one active component. Doses are also required to be separated from foods high in oxalic or phytic acid. Taking antacids that contain either magnesium or calcium is also typically avoided.


Q: What happens if I drink alcohol while I am on Senfem?

The active Vitamin D analog component, Dihydrotachysterol, has a documented interaction with alcohol. This interaction is classified as 'moderate' and may impact how the drug is processed in the body. Discussing alcohol consumption with a healthcare provider is generally recommended while using this medicine.


Q: Do older adults (seniors) need to take a lower amount of Senfem?

Official regulatory documents do not specify a mandatory lower dose for older adults. However, these patients are documented as requiring closer monitoring of their renal function and blood calcium levels. This increased monitoring is due to the cumulative nature of the Vitamin D component and a potentially higher risk of toxicity.


Q: Can people who have a history of liver problems use Senfem?

The use of Senfem is restricted in patients who have pre-existing severe hepatic impairment (liver damage). Furthermore, the Vitamin D analog component has a documented disease interaction with various forms of hepatobiliary dysfunction. Patients with a history of liver problems require medical caution and strict monitoring during treatment.


Q: Is Senfem appropriate for use by teenagers or children?

Use in pediatric patients is explicitly established only for specific therapeutic indications, such as the treatment of rickets or specific hypocalcemic conditions. It is not generally approved or recommended for use by all teenagers or children outside of these medically labeled therapeutic indications.


Q: Are there any long-term effects associated with using Senfem for many years?

Official information indicates that the risk of serious adverse reactions, including Severe Hypercalcemia and Renal Failure, increases with chronic and long-term high-dose exposure. Chronic toxicity from the Vitamin A component (Retinyl Palmitate) can also lead to liver damage and bone thinning over time. Continuous medical monitoring is mandatory.


Q: Why is Senfem sometimes given in combination with other medications?

Senfem is a combination of a Vitamin D analog and a Calcium supplement. These components are frequently administered alongside other supplements, such as phosphate, to manage complex conditions like Hypoparathyroidism or Rickets. This co-administration is done to ensure a balanced mineral replacement strategy.


Q: Is it normal to feel a bit nauseous when first starting Senfem?

Nausea is listed in official documents as a commonly observed effect and is also cited as an early symptom of Hypercalcemia, the primary toxicity risk. For these reasons, it is a symptom that patients are advised to watch for particularly when beginning treatment.


Q: Can Senfem affect blood pressure readings?

Official documents indicate that Hypercalcemia (elevated calcium levels), which is the primary toxicity risk associated with the drug, can potentially cause or worsen hypertension (high blood pressure). Monitoring blood pressure may be part of the care plan.


Q: Does Senfem cause weight gain or weight loss?

The drug is not commonly known to cause weight changes as a primary side effect. However, loss of appetite (anorexia) and subsequent unintentional weight loss are documented symptoms associated with the more serious adverse reaction of Hypercalcemia.


Q: What should I watch out for during the first week of taking Senfem?

Patients should monitor closely for early signs of Hypercalcemia during the first week. These symptoms, including headache, nausea, loss of appetite, increased thirst (polydipsia), and unusual weakness, are documented reasons to contact a healthcare provider promptly.


Q: Why do some people say they feel nervous after starting Senfem?

The primary toxicity risk, Hypercalcemia, can affect the central nervous system (CNS). Related CNS effects are documented to include confusion and mental status changes, which may be experienced or described by some patients as nervousness or anxiety.


Q: Can Senfem affect the results of other medical tests?

Yes. Since the medication is designed to regulate calcium and phosphate metabolism, it directly impacts the concentration of these minerals in the body. Consequently, it will affect the results of all blood and urine tests that measure calcium and phosphate levels, which require monitoring.


Q: How long does Senfem stay in your system after the last dose?

Official pharmacological data indicates that the effects of the active Vitamin D analog component (Dihydrotachysterol) may persist in the body for an extended time. The time for the effects to wear off, known as the offset of action, is approximately 7 to 21 days after the last dose.


Q: If I have an allergic reaction to Senfem, what are the signs?

Although allergic reactions are uncommon, symptoms of a severe hypersensitivity reaction may include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. These signs are documented reasons to seek medical help immediately.


Q: Is the full benefit of Senfem usually seen immediately or over time?

The full therapeutic benefit is generally seen over time. The onset of action for the active components is documented to take several days. Consistent adherence to the regimen is necessary to achieve the full beneficial effects on mineral balance.


Q: Does Senfem cause problems with vision?

Yes, potential problems with vision have been documented as symptoms associated with Hypervitaminosis A or D toxicity. These can include blurred vision, increased sensitivity to light, or redness and discharge from the eye.


Q: Can Senfem make pre-existing mental health conditions worse?

Official information indicates that Hypercalcemia can cause CNS symptoms, including confusion and mental status changes. These effects may resemble or potentially worsen symptoms of pre-existing conditions like anxiety and depression.


Q: Does Senfem interfere with sleep patterns?

Sleep interference is not listed as a primary side effect of the drug itself. However, polyuria (frequent urination) and nocturia (urinating more often at night) are documented signs of Hypercalcemia that can disrupt normal sleep patterns.


Q: Can I crush or split Senfem tablets?

Unless explicit instructions are given by a healthcare provider, the tablet is generally to be swallowed whole without crushing or chewing. Crushing or splitting certain oral dosage forms, especially extended-release tablets, can increase the risk of side effects.

How should Senfem be stored and disposed of?

How to Store and Dispose of Senfem?

Official regulatory guidelines define specific conditions for storing and disposing of Senfem, a product containing a calcium salt and fat-soluble vitamins.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Keep the medicine in its original, tightly closed container and protect it from both light and moisture. Avoid storing in high-humidity areas like a bathroom.
Safety The product must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Senfem must not be disposed of by flushing it down the toilet or drain, as this can harm the environment. The product should be discarded through an official drug take-back program or as instructed by local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Senfem found in:

A-Z Index: